Author

Priti Paul

Observed name: Priti Gautam Paul

Institutions: National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research

Observed institutions: National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research

ORCID: 0000-0001-6274-3713

Observed ORCID: 0000-0001-6274-3713

OpenAlex ID: A5043983009

Traversing the diverse avenues of exopolysaccharides-based nanocarriers in the management of cancer

2023 · Priti Paul, Rahul Nair, et al. · Carbohydrate Polymers · 42

Fabrication of β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin inclusion complexes of Palbociclib: Physicochemical characterization, solubility enhancement, in -silico studies, in vitro assessment in MDA-MB-231 cell line

2024 · Priti Paul, Ujala Gupta, et al. · Journal of Molecular Liquids · 37

Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic

2023 · Rahul Nair, Priti Paul, et al. · Carbohydrate Polymers · 32

Nanomedicine: A pragmatic approach for tackling melanoma skin cancer

2023 · Vikram Mohanlal Prajapat, Srushti Mahajan, et al. · Journal of Drug Delivery Science and Technology · 27

A comprehensive review of the biomaterial-based multifunctional nanocarriers for therapeutic applications in breast cancer

2023 · Arti Shettiwar, Ujala Gupta, et al. · Journal of Drug Delivery Science and Technology · 17

Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives

2025 · Tanmoy Kanp, Anish Dhuri, et al. · ACS Applied Bio Materials · 14

Emerging Paradigms in Nanozyme: Strategies in Fabrication, Cancer Targeting, and Biosensing

2025 · Bhavana Gajare, Tanmoy Kanp, et al. · ACS Applied Bio Materials · 11

Fabrication of amorphous solid dispersion of Entacapone for enhanced solubility and dissolution rate: Morphology, solid state characterization, In silico molecular docking studies

2024 · Anish Dhuri, Tanmoy Kanp, et al. · Journal of Molecular Structure · 11

Unveiling multifaceted avenues of echogenic liposomes: Properties, preparation, and potential applications

2024 · Nandkishor Rajankar, Mayur Aalhate, et al. · Journal of Drug Delivery Science and Technology · 10

The Neoteric Paradigm of Biomolecule-Functionalized Albumin-Based Targeted Cancer Therapeutics

2024 · Swati Gunjkar, Ujala Gupta, et al. · AAPS PharmSciTech · 7

Stimuli-Responsive and Receptor-Targeted Carbon Nanotubes for Multimodal Cancer Therapy and Diagnosis

2025 · Sourabh Tapekar, Anish Dhuri, et al. · Molecular Pharmaceutics · 6

Leveraging Self-Healing Hydrogels for Cancer Management: Synthesis, Targeting Strategies, and Clinical Progress

2025 · Vaibhav Dhumal, Rahul Nair, et al. · ACS Applied Bio Materials · 4

Implication of colloidal therapeutics in the treatment of vitiligo: Portray of signaling cascade, current drug-targets and preclinical and clinical evidences

2024 · Priti Paul, Harithasree Veerabomma, et al. · Journal of Drug Delivery Science and Technology · 2

Emerging Era of “Biotics”: Prebiotics, Probiotics, and Synbiotics

2024 · Rahul Nair, Priti Paul, et al. · Springer eBooks · 2

Augmenting Therapeutic Performance of CDK4/6 Inhibitor through a Nanocrystal-Integrated Thermoresponsive In Situ Gel Platform

2026 · Vaibhav Dhumal, Bharath Manoharan, et al. · Crystal Growth & Design · 1

Correction to: Emerging Era of “Biotics”: Prebiotics, Probiotics, and Synbiotics

2024 · Rahul Nair, Priti Paul, et al. · Springer eBooks · 1

PDF

PEGylated Lipidic Nanocapsules Encapsulating Olaparib for Breast Cancer Therapy: In Vitro and In Vivo Evaluation

2026 · Sourabh Tapekar, Anish Dhuri, et al. · Journal of Pharmaceutical Innovation

Multifunctional Hybrid Nano-Platform for Co-Delivery of Erlotinib and Silibinin: A Nanotherapeutic Strategy Against Triple-Negative Breast Cancer

2026 · Bhavana Gajare, Tanmoy Kanp, et al. · Research Square

PDF

Synthesis of docusate-based lipophilic salts for engineering Abemaciclib: From molecular interactions to lipid formulations

2026 · Yadav Hira Kamlesh, Tanmoy Kanp, et al. · Journal of Drug Delivery Science and Technology

Breast cancer stem cell targeting

2025 · Samanwita Khanra, Sudhakar Kothandan, et al. · Elsevier eBooks

Contributors

2025 · Mayur Aalhate, Vaishali Bambal, et al. · Elsevier eBooks

HER2-positive (HER2+) & HER2-negative (HER2−) targeted therapies

2025 · Vaishali Bambal, Seema S Rathore, et al. · Elsevier eBooks

Chemotherapeutic drugs and their side effects, BC biomarkers, detection, levels of targeting, and EPR

2025 · Rahul Nair, Priti Paul, et al. · Elsevier eBooks

Nutraceuticals in the Prevention of Cancer

2024 · Priti Paul, Rahul Nair, et al. · Food bioactive ingredients

Works count: 24

Citation count: 224

H-index: 9

I10-index: 9